Rheumatoid arthritis
Conditions
Interventions
Transdermal administration of 5g of Dovonex(r) ointment 50ug/g twice daily for 7 days. 7 days administration and following 7 days wash-out period are repeated twice.
Sponsors
Medical Co.LTA PS Clinic
Medical Co.LTA PS Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, Patients with rheumatoid arthritis diagnosed based on either ACR 1987 revised criteria or 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis. 2, Patients currently treated with antirheumatic drug (except for Cyclosporine and Tacrolimus) 3, 20 years of age or older at the time of consent. 4, Patients who are not during pregnancy or lactation. 5, Patients who consented in writing prior to the commencement of the study procedure.
Exclusion criteria
Exclusion criteria: 1, Patients with other systemic autoimmune disease (e.g. systemic erythematosus). 2, Patients with history of hypersensitivity to Calcipotriol. 3, Patients with or with the risk of hypercalcemia, or whose serum calcium level exceed normal range. 4, Patients currently treated with Calcineurin antagonist (Cyclosporine or Tacrolimus). 5, Patients currently treated with anti-osteoporosis drugs (Vitamin D3, PTH). 6, Patients whose eGFR is 60 or lower. 7, Patients treated for bacterial infection within 30 days prior to the first administration of the study drug. 8, Uncooperative patients who might not comply with the protocol procedure. 9, Patients with malignant tumor requiring treatment within past 5 years. 10, Patients judged inappropriate for this study by principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of Treg are evaluated before and 8 days after transermal administration of Dovonex(r) ointment 50ug/g. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate change in disease activity using RA activity indexes | — |
Countries
Japan
Contacts
Public ContactMIDORI SUZAKI
Medical Co.LTA PS Clinic Nurse
Outcome results
None listed